novel
coronaviru
emerg
pathogen
first
describ
late
decemb
caus
sever
respiratori
infect
human
sinc
outbreak
intern
attent
rais
develop
treatment
control
option
type
immunotherapi
immunotherapi
effect
method
fight
similar
viral
infect
sarscov
merscov
method
includ
sever
type
vaccin
monoclon
antibodi
candid
etc
systemat
review
articl
design
evalu
exist
evid
experi
relat
immunotherapi
web
scienc
isi
pubm
scopu
databas
use
search
suitabl
keyword
novel
coronaviru
immunotherapi
interleukin
vaccin
relat
word
relev
public
present
systemat
review
perform
base
prisma
protocol
data
extract
qualiti
valuat
articl
perform
two
review
articl
result
search
base
inclus
exclus
criteria
articl
includ
final
review
conclus
studi
demonstr
although
seriou
research
done
subject
time
write
articl
similar
studi
relat
virus
show
notabl
result
immunotherapi
viru
also
suitabl
option
larg
envelop
viru
posit
sens
singlestrand
rna
genom
third
known
coronaviru
sarscov
merscov
first
identifi
late
decemb
caus
sever
respiratori
ill
pneumonialik
infect
human
declar
pandem
outbreak
novel
coronaviru
global
health
emerg
immunotherapi
effici
therapeut
option
intervent
viral
infect
immunotherapi
attempt
success
fight
similar
virus
sarscov
merscov
main
method
regard
includ
sever
vaccin
monoclon
antibodi
candid
furthermor
accord
exist
evid
fight
viral
infect
ebola
influenza
sar
mer
plasma
exchang
like
reduc
viral
load
diseas
mortal
sarscov
virus
entri
host
cell
mediat
interact
receptorbind
domain
rbd
protein
viru
outermembran
angiotensinconvert
enzym
cell
protein
major
potenti
target
immunotherapi
increas
knowledg
merscov
sarscov
immunotherapi
recent
year
might
increas
opportun
design
effect
therapeut
novel
coronaviru
despit
rel
high
ident
rbd
sarsco
necessari
develop
novel
monoclon
antibodi
could
bind
specif
rbd
sinc
potent
sarscovspecif
neutral
antibodi
eg
target
bind
site
sarscov
fail
bind
spike
protein
impli
differ
rbd
sarscov
purpos
articl
review
immunotherapeut
attempt
list
current
investig
immunotherapeut
strategi
present
systemat
review
articl
perform
base
prisma
protocol
tabl
tabl
titl
abstract
separ
review
two
author
aaj
sgh
detect
potenti
relat
articl
full
text
articl
appear
confus
evalu
determin
appropri
inclus
studi
review
articl
categori
immunotherapi
monoclon
antibodi
interleukin
vaccin
etc
three
coronavirus
must
mention
use
immunotherapi
treatment
control
articl
abstract
exclud
review
articl
also
exclud
sar
mer
without
discuss
outlook
data
articl
extract
independ
two
review
fill
tabl
item
qualiti
public
evalu
two
independ
review
aaj
sgh
review
address
domain
type
immunotherapi
dedic
virus
treatment
intervent
accompani
anoth
treatment
number
patient
treat
percent
improv
outcom
result
clinic
outcom
possibl
conduct
metaanalysi
enough
proper
research
studi
subject
retriev
total
potenti
elig
articl
initi
databas
search
articl
exclud
duplic
articl
also
exclud
review
articl
address
virusess
full
text
access
therefor
total
articl
includ
final
analysi
fig
accord
inclus
criteria
state
protocol
articl
includ
english
languag
without
date
restrict
updat
search
process
pubm
wo
scopu
endnot
librari
version
thomson
reuter
use
import
citat
databas
duplic
citat
remov
titl
abstract
remaind
search
result
review
intern
immunopharmacolog
tabl
main
characterist
includ
studi
immunotherapi
potenti
untest
base
cell
epitop
sarscov
aminjafari
ghasemi
intern
immunopharmacolog
author
exclud
irrelev
studi
full
text
remaind
citat
collect
screen
data
extract
includ
studi
origin
articl
publish
public
relat
aim
manag
control
corona
viru
pandem
sever
type
immunotherapi
accord
extract
data
tabl
immunotherapi
attempt
includ
polyclon
antibodi
plasma
therapi
polypeptid
hormon
matur
cell
immunoglubolin
immunoadhesin
monoclon
antibodi
intervent
viralvector
nanoparticl
inactiv
whole
viru
dna
vaccin
monoclon
antibodi
use
sarscov
hold
promis
use
plasma
therapi
immunoglobulin
intervent
infect
patient
could
improv
clinic
outcom
vaccin
immunoadhesin
test
yet
prefer
immunotherapi
method
monoclon
antibodi
perform
sar
howev
method
yet
test
articl
field
review
articl
recommend
immunotherapi
reason
evid
previou
studi
two
coronavirus
sarscov
merscov
one
clinic
trial
studi
field
mention
method
sarscov
receptor
viru
entri
potenti
biotherapeut
prevent
sar
entri
could
extrapol
use
among
immunotherapi
approach
block
viru
attach
entri
monoclon
antibodi
prefer
due
specif
puriti
low
risk
bloodborn
pathogen
contamin
safeti
compar
serum
therapi
intraven
immunoglobulin
prepar
promis
result
target
spike
protein
sarscov
merscov
monoclon
antibodi
encourag
research
use
fight
monoclon
antibodi
cocktail
combin
differ
monoclon
antibodi
recogn
differ
epitop
viral
surfac
may
increas
effect
viru
neutral
target
immunotherapi
seem
promis
cytokin
among
cytokin
specif
come
elev
correl
inflammatori
cytokin
storm
sever
therefor
target
receptor
siltuximab
tocilizumab
monoclon
antibodi
mab
could
mitig
cytokin
stormrel
symptom
sever
patient
despit
major
progress
develop
monoclon
antibodybas
passiv
immunotherapi
coronaviru
infect
market
monoclon
antibodi
limit
use
antibodi
largescal
product
monoclon
antibodi
clinic
applic
labori
expens
timeconsum
design
develop
advanc
protein
product
platform
express
system
urgent
provid
effici
monoclon
antibodi
afford
cost
short
time
although
research
test
approv
vaccin
antivir
therapeut
agent
treat
vaccin
success
due
specif
structur
viru
furthermor
exist
evid
immunotherapi
sarscov
merscov
hold
promis
use
evid
systemat
review
immunotherapi
effici
therapeut
option
intervent
main
method
regard
use
immunoglobulin
plasma
therapi
improv
clinic
outcom
infect
patient
